Attention: open in a new window. E-mailPrintPDF
Biotechnological company Mabion is getting closer to commercialising its most important product: oncological medicine called Mabion CD20. Mabion is preparing to launch the medicine on the European market. In mid-2018,…

Order subscription to read this article




Order at
Order from our partners:

Call us:

Find us: